_barnsley-aampe-shown-39full-to-capacity39-in-tv-documentary.jpg "Barnsley A&E shown 'full to capacity' in TV documentary from licking women39s patient Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 1:10
👁 View: 2.3M times
✓ Published: 15-May-2024
👁 View: 2.3M times
✓ Published: 15-May-2024
Description:
This clip is from the Channel 5 show Casualty 24/7: Every Second Counts
This clip is from the Channel 5 show Casualty 24/7: Every Second Counts
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_lesbian-armpit-licking-v.webp "Lynette Green 5")
_kissing-belly-licking.webp "bp4mp")
_new-analysis-suggests-long-term-effectiveness-for-wegovy-users.webp "New Analysis Suggests , Long-Term Effectiveness , for Wegovy Users .<br/>NBC reports that patients taking <br/>Novo Nordisk's obesity treatment maintain <br/>an average of 10% weight loss over four years.<br/>The news potentially boosts the <br/>drugmaker's push for Wegovy to be <br/>covered by insurers and governments. .<br/>The company submitted long-term <br/>findings at the European Congress <br/>on Obesity in Venice, Italy. .<br/>This is the longest study <br/>we’ve conducted so far of <br/>semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC.<br/>We see that once the majority <br/>of the weight loss is accrued, <br/>you don’t go back and start <br/>to increase in weight<br/>if you stay on the drug, Martin Holst Lange, Novo’s head of development, via NBC.<br/>According to another analysis published by <br/>the drugmaker, approximately 17% of trial participants stopped using the treatment <br/>due to side effects like nausea. .<br/>The costly treatment ranges from $200 <br/>to nearly $2,000 per month in the ten <br/>countries where the drug is available.<br/>NBC reports that Novo Nordisk was the <br/>first drugmaker to market GLP-1 agonists, <br/>originally developed as a diabetes treatment, <br/>to address record high obesity rates.<br/>NBC reports that Novo Nordisk was the <br/>first drugmaker to market GLP-1 agonists, <br/>originally developed as a diabetes treatment, <br/>to address record high obesity rates.<br/>Rival Eli Lilly launched its drug <br/>Zepbound in the United States <br/>in December of 2023. .<br/>Neither drugmaker has managed <br/>to produce enough of the <br/>treatment to meet surging demand")
_don39t-lk-woman39s-body-part-untill-you-see-this-interestingpsychologyfacts.webp "Think Psychology")
⏲ 2 minutes 49 seconds 👁 90.3K
_lesbian-armpit-licking-v.jpg)
_kissing-belly-licking.jpg)
_new-analysis-suggests-long-term-effectiveness-for-wegovy-users.jpg)
_don39t-lk-woman39s-body-part-untill-you-see-this-interestingpsychologyfacts.jpg)
![[+]](/images/menu.gif){kind=small}